JPMorgan Chase & Co. Sells 23,935 Shares of Stevanato Group S.p.A. (NYSE:STVN)

JPMorgan Chase & Co. trimmed its position in Stevanato Group S.p.A. (NYSE:STVN) by 78.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,458 shares of the company’s stock after selling 23,935 shares during the period. JPMorgan Chase & Co.’s holdings in Stevanato Group were worth $129,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in STVN. Squarepoint Ops LLC boosted its stake in Stevanato Group by 65.6% in the second quarter. Squarepoint Ops LLC now owns 17,302 shares of the company’s stock valued at $317,000 after acquiring an additional 6,853 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Stevanato Group by 222.3% in the second quarter. The Manufacturers Life Insurance Company now owns 251,606 shares of the company’s stock valued at $4,614,000 after acquiring an additional 173,546 shares during the last quarter. Truist Financial Corp boosted its stake in Stevanato Group by 47.0% in the second quarter. Truist Financial Corp now owns 26,034 shares of the company’s stock valued at $477,000 after acquiring an additional 8,321 shares during the last quarter. SG Americas Securities LLC purchased a new position in Stevanato Group in the third quarter valued at about $263,000. Finally, nVerses Capital LLC purchased a new position in Stevanato Group in the third quarter valued at about $84,000.

Stevanato Group Stock Performance

Shares of STVN stock opened at €22.31 ($22.77) on Monday. The stock has a market capitalization of $6.76 billion, a P/E ratio of 47.47, a PEG ratio of 7.42 and a beta of 0.56. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The firm’s 50 day moving average is €21.73 and its 200 day moving average is €20.50. Stevanato Group S.p.A. has a 12 month low of €16.56 ($16.90) and a 12 month high of €34.73 ($35.44).

Stevanato Group (NYSE:STVN) last announced its quarterly earnings results on Tuesday, November 5th. The company reported €0.12 ($0.12) EPS for the quarter, missing analysts’ consensus estimates of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €277.90 million for the quarter, compared to analysts’ expectations of €274.36 million. During the same quarter in the previous year, the company posted $0.16 earnings per share. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on STVN shares. Wolfe Research started coverage on shares of Stevanato Group in a research note on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price on the stock. Bank of America boosted their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Finally, Morgan Stanley restated an “equal weight” rating and set a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of €28.60 ($29.18).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.